Related Experiment Video
Updated: May 12, 2026

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
Published on: October 11, 2024
Leg weakness in a lung transplant patient
T Moua1, S A Rizza, C C Kennedy
1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA. moua.teng@mayo.edu
Insights
Progressive multifocal leukoencephalopathy (PML) in lung transplant patients is a rare but serious JC polyomavirus (JCV) reactivation. Management is challenging due to limited therapies and risks of graft rejection when reducing immunosuppression.
Area of Science:
- Neuroscience
- Infectious Diseases
- Transplantation Immunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by JC polyomavirus (JCV).
- JCV reactivation typically occurs in immunosuppressed individuals, including those with HIV/AIDS, hematological malignancies, and solid organ transplant recipients.
- PML presents with focal neurologic deficits and is often diagnosed via neuroimaging and brain biopsy.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is associated with JC polyomavirus (JCV) infection of central nervous system oligodendrocytes resulting in demyelinization and progressive focal neurologic deficits. Reactivation of dormant JCV occurs in the setting of immunosuppression, most commonly in patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) or hematological malignancies. PML has also been reported in solid organ transplant recipients. We report the case of a 61-year-old man after bilateral lung transplantation for chronic hypersensitivity pneumonitis who presented with leg weakness, cognitive decline, and expressive aphasia at 5 months post transplantation. Magnetic resonance imaging and brain biopsy were consistent with PML. Treatment attempt with cytarabine was unsuccessful, and immunomodulation resulted in recurrent grade A3 rejection. The difficulty of managing PML in lung transplant patients is highlighted by the lack of directed therapy and risk of graft rejection or failure with attempts at decreasing immunosuppression.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Atelectasis II: Pathophysiology

